Floatz logo

Lisaftoclax

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sun Yat-sen UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Relapsed/Refractory Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Selinexor
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3BB
Dexasone
City of Hope Medical Center
Phase 2/3BB
Cyclophosphamide
Nathan Denlinger
Phase 3BB
ISOCYCLOPHOSPHAMIDE
University of California, Davis
Phase 3BB
Axicabtagene Ciloleucel
Zhujiang Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Lisaftoclax is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BBB
Indicative · Phase 3
73 / 100
View asset →
acute myeloid leukemiaActive
B
Indicative · Phase 3
63 / 100
View asset →
diffuse large B-cell lymphomaActive
B
Indicative · Phase 2
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →